Xenon Pharmaceuticals XENE Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's financing cash flow?
- Xenon Pharmaceuticals (XENE) reported financing cash flow of $843.01M in Q1 2026.
- How has Xenon Pharmaceuticals's financing cash flow changed year-over-year?
- Xenon Pharmaceuticals's financing cash flow increased by 73141.8% year-over-year, from $1.15M to $843.01M.
- What is the long-term trend for Xenon Pharmaceuticals's financing cash flow?
- Over 3 years (2021 to 2025), Xenon Pharmaceuticals's financing cash flow has grown at a -36.0% compound annual growth rate (CAGR), from $447.54M to $117.11M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.